CClinicalTrials.gg
RecruitingNCT07351175Updated Feb 11, 2026

Investigating The Potential Of A Hay-Aged Cheese To Reduce Cholesterol As Mediated By Changes In The Gut Microbiome

An interventional study of Hay-aged cheese and Cheddar control in Cholesterol, Elevated, sponsored by Anisha Wijeyesekera. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-11.

Sponsored by Anisha Wijeyesekera · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The goal of this intervention trial is to investigate the potential of an artisan cheese aged in hay to induce changes in the gut microbiota in a manner which mediates a reduction in total cholesterol in participants with elevated total cholesterol. The main questions it aims to answer are:

Does daily consumption of a hay aged cheese over 12 weeks reduce total cholesterol by at least 0.5mmol/l when compared the control cheese (cheddar)? Are changes in total cholesterol level reflected in changes in gut microbiota composition and activity as measured by deoxyribonucleic acid (DNA) sequencing of stool composition and short chain fatty acid levels in urine?

Participants will be asked to consume 30g portions of cheese every day for 12 weeks. This study is conducted in parallel, with participants either allocated onto the control arm (cheddar) or intervention arm (hay-aged cheese). Blood, stool, and urine samples will be taken throughout the trial, body mass index (BMI) and blood pressure will also be measured.

Read the detailed description

Cheese production involves the use of starter culture bacteria, many of which are species with recognised probiotic potential. Additionally, the food matrix of protein and fat is thought to protect these cultures during human digestion, allowing them to reach the large intestine alive. Previous studies have indicated that cultures present in cheese can persist in the gut microbiome and exert a positive effect. Further studies have indicated that regular cheese consumption, despite having a high proportion of saturated fats, has been associated with lower cholesterol levels. This is thought to be mediated by the food matrix which reduces the release of fat during digestion, and recent work by the investigators has suggested that changes in the gut microbiota activity induced by cheese consumption may also have a role. This laboratory work has shown that cheese can boost the production of propionate (a microbially derived metabolite) in a gut model system, particularly a variety of cheese that is aged in hay (Witheridge-in-hay). Propionate in the gut is known to have a role in cholesterol regulation. The hypothesis is that cheese is a source of probiotics, and the hay on the rind of Witheridge-in-hay acts in a prebiotic manner; therefore this cheese is synbiotic and has the potential to confer multiple health benefits including reduced total cholesterol concentration mediated by a change in gut microbiota composition. In the proposed study, participants (ages 18-65, with elevated cholesterol between 5.5-7.5mmol/l) will consume a thirty-gram portion of cheese a day, either Witheridge-in-hay or cheddar as a control, for twelve weeks. Effects will be determined by collecting stool samples, urine, and blood from participants to measure bacterial composition, fermentation end products, and cholesterol levels respectively, as well as body mass index (BMI) measurements and blood pressure for further assessment of cardiovascular and weight gain effects. Samples will be collected at baseline, mid-intervention, and post-intervention.

02

Conditions studied

  • Cholesterol, Elevated
03

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Participants aged 18 to 65 years old
  • Regular consumer of cheese
  • In generally good health but with total cholesterol level between 5.5-7.5 mmol/l and body mass index (BMI) between 18-32 kg/m2 at screening visit
  • Willing and able to comply with study instructions

Exclusion criteria

Exclusion Criteria:

  • Use of antibiotics in the last 6 months prior to the study.
  • Use of prebiotics, probiotics, laxatives, anti-spasmodic, anti-diarrhoeals, herb supplements in the last 4 weeks prior to or during the study period.
  • Any chronic gut disorders/disease such as irritable bowel syndrome, inflammatory bowel disease, etc or other conditions that might affect the gut environment e.g. coeliac disease.
  • High blood pressure, anaemia, high blood lipids (total cholesterol >7.5mmol/l), or inflammatory conditions
  • Taking medication for anaemia, high blood pressure, high blood lipids , inflammatory conditions or depression
  • Anyone diagnosed with vitamin deficiencies, diabetes, heart disease (previous stroke or heart attack) or have a pacemaker, kidney, bowel or liver diseases, cancer or hormone abnormalities.
  • Pregnant, lactating, breast feeding or planning a pregnancy within the next 6 months
  • Peri- or postmenopausal women
  • Lost more than 3kg of body weight in the last 6 months
  • Food allergies and intolerances
  • Participants currently involved or will be involved in another clinical or food study in the previous 3 months
04

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Hay-aged cheese

    An artisan cheese aged in hay - this is a semi-hard cheese, aged for 9 months, with hay present on the rind.

    Dietary Supplement: Hay-aged cheese

  • Active comparator
    Cheddar

    Industrial made cheddar, vintage aged. Vacuum packed.

    Dietary Supplement: Cheddar control

Interventions

  • Dietary supplementHay-aged cheese

    This cheese is speculated to have both probiotic properties, from the starter cultures present in the cheese, and prebiotic properties, from the hay on the rind, making this cheese synbiotic.

  • Dietary supplementCheddar control

    This cheese is an industrial made cheddar, it still has potential probiotic properties due to the starter cultures used, but no prebiotic potential.

05

What researchers measure

Primary outcomes

  1. Change in total cholesterol concentration

    Total cholesterol levels will be measured at the beginning and end of the trial. Does the daily consumption of cheese have an effect on total cholesterol levels, and does consumption of a hay-aged cheese influence total cholesterol beyond that for cheddar?

    Time frame: 12 weeks

Secondary outcomes

  1. Change in faecal microbiota composition

    Stool samples will be collected on 3 occasions throughout the trial. 16S sequencing will be used to assess changes in microbial populations in response to daily cheese consumption, comparing cheddar and the hay-aged cheese.

    Time frame: 12 weeks

  2. Change in production of SCFA by the gut microbiota

    Gas chromatography will be used to analyse changes in SCFA content in stool and urine, collected on 3 and 5 occasions throughout the trial, respectively. This will help to assess the activity of the gut microbiota induced by the cheese intervention.

    Time frame: 12 weeks

06

Study locations

1 of 1 sites recruiting
  • University of Reading, Department of Food and Nutritional Sciences
    Reading, RG6 6UR, United Kingdom
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07351175
Lead sponsor
Anisha Wijeyesekera
Responsible party
Anisha Wijeyesekera (Associate Professor, University of Reading) — Sponsor-investigator
First posted
Jan 20, 2026
Start date
Jan 26, 2026
Primary completion
Nov 2026 (estimated)
Completion
Jan 2027 (estimated)
Last update
Feb 11, 2026

Study contacts

Sabrina I Longley
Contact
s.i.c.longley@pgr.reading.ac.uk
+44 7587142910
Anisha Wijeyesekera
Contact
a.wijeyesekera@reading.ac.uk
Anisha Wijeyesekera
principal investigator · University of Reading

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion